^
Association details:
| Biomarker: | CCND1-H |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of biomarkers associated with therapeutic resistance: quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer
Published date:
11/17/2020
Excerpt:
736 patients (260 HR+HER2-, 252 TN, 142 HR+HER2-, and 82 HR-HER2+; over 8 arms: 194 Ctr, 105 neratinib (N), 63 veliparib/carboplatin (VC), 128 AMG386 (anti-ANG1/2), 87 MK2206 (anti-AKT), 43 TH/pertuzumab (P), 49 TDM1/P, and 67 pembrolizumab (Pembro)) with pCR...Within individual arms, high Cyclin D1 predicted non-response in VC, control, and AMG386; and trends toward association in Pembro and N....
Secondary therapy:
carboplatin
